Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Pronzato

Showing results (21-30 of 95) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|June 1, 2013
Multigene assays and molecular markers in breast cancer: systematic review of health economic analysesRoman Rouzier, Paolo Pronzato, Elisabeth Chéreau, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2009
Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxanePaolo Spallarossa, Paola Altieri, Paolo Pronzato, et al.
Healthcare (Basel, Switzerland)|January 8, 2025
The Ligurian Experience in the Management of Lung Cancer: Organizational Models and New PerspectivesDaniela Amicizia, Francesca Marchini, Paolo Pronzato, et al.
Tumori|June 16, 2020
Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM)Antonino C Tralongo, Andrea Antonuzzo, Paolo Pronzato, et al.
Journal of the National Cancer Institute|December 27, 2007
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trialsAlessandra Gennari, Maria Pia Sormani, Paolo Pronzato, et al.
Expert Review of Anticancer Therapy|October 18, 2012
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patientsLucia Del Mastro, Matteo Lambertini, Claudia Bighin, et al.
Future Oncology (London, England)|April 25, 2020
Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in ItalyMarco Danova, Paolo Pronzato, Ylenia Ingrasciotta, et al.
Melanoma Research|October 15, 2013
The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survivalStefania Vecchio, Francesco Spagnolo, Domenico F Merlo, et al.
Expert Review of Clinical Pharmacology|August 23, 2016
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patientsFrancesca Poggio, Matteo Lambertini, Eva Blondeaux, et al.
Leukemia Research|April 7, 2012
Stevens-Johnson syndrome after treatment with bendamustineMatteo Lambertini, Lucia Del Mastro, Giovanni Gardin, et al.
Pageof 10

Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|June 1, 2013
Multigene assays and molecular markers in breast cancer: systematic review of health economic analysesRoman Rouzier, Paolo Pronzato, Elisabeth Chéreau, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2009
Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxanePaolo Spallarossa, Paola Altieri, Paolo Pronzato, et al.
Healthcare (Basel, Switzerland)|January 8, 2025
The Ligurian Experience in the Management of Lung Cancer: Organizational Models and New PerspectivesDaniela Amicizia, Francesca Marchini, Paolo Pronzato, et al.
Tumori|June 16, 2020
Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM)Antonino C Tralongo, Andrea Antonuzzo, Paolo Pronzato, et al.
Journal of the National Cancer Institute|December 27, 2007
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trialsAlessandra Gennari, Maria Pia Sormani, Paolo Pronzato, et al.
Expert Review of Anticancer Therapy|October 18, 2012
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patientsLucia Del Mastro, Matteo Lambertini, Claudia Bighin, et al.
Future Oncology (London, England)|April 25, 2020
Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in ItalyMarco Danova, Paolo Pronzato, Ylenia Ingrasciotta, et al.
Melanoma Research|October 15, 2013
The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survivalStefania Vecchio, Francesco Spagnolo, Domenico F Merlo, et al.
Expert Review of Clinical Pharmacology|August 23, 2016
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patientsFrancesca Poggio, Matteo Lambertini, Eva Blondeaux, et al.
Leukemia Research|April 7, 2012
Stevens-Johnson syndrome after treatment with bendamustineMatteo Lambertini, Lucia Del Mastro, Giovanni Gardin, et al.
Pageof 10